OS Therapies Incorporated
OSTXAMEXHealthcareBiotechnology
Latest quote
$1.58
+$0.01 · +0.63%
OSTX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
44
Neutral
Sentiment
56
Mixed
Risk resilience
45
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteOS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Paul A. Romness
- Listed since
- Aug 1, 2024
- Employees
- 5
Market position
- Volume
- 362.37K
- 0.54× average
- Average volume
- 675.58K
- Average daily volume
- Market cap
- 72.41M USD
- Beta
- -0.73
- Market reference 1
Financials
Financial snapshot
Latest / TTMFinancial health
- Altman Z-score
- 2.76
- Piotroski F-score
- 2 of 9
Earnings
- Latest fiscal-year EPS
- -0.98
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
- Next fiscal-year EPS consensus
- -0.76
- FY2026 · 2 analysts
- Next fiscal-year revenue consensus
- 2M USD
- FY2026 · 3 analysts
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
OSTX peers
Continue in GoAI
Research OSTXresearch.disclaimer